Zhi-rong Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1107602/publications.pdf

Version: 2024-02-01

840776 794594 33 429 11 19 citations h-index g-index papers 34 34 34 765 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Regulation profile of the intestinal peptide transporter 1 (PepT1). Drug Design, Development and Therapy, 2017, Volume 11, 3511-3517.	4.3	59
2	Sensitive bioassay for the simultaneous determination of pseudoephedrine and cetirizine in human plasma by liquid-chromatography–ion trap spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 207-212.	2.8	34
3	MASS SPECTROMETRYâ€BASED PERSONALIZED DRUG THERAPY. Mass Spectrometry Reviews, 2020, 39, 523-552	2.5.4	31
4	Pseudogenes of annexin A2, novel prognosis biomarkers for diffuse gliomas. Oncotarget, 2017, 8, 106962-106975.	1.8	31
5	Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers. Scientific Reports, 2017, 7, 4709.	3.3	28
6	Identification of Common Genes Refers to Colorectal Carcinogenesis with Paired Cancer and Noncancer Samples. Disease Markers, 2018, 2018, 1-7.	1.3	26
7	Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy. Biomedicine and Pharmacotherapy, 2019, 114, 108864.	5.6	22
8	DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma. OncoTargets and Therapy, 2017, Volume 10, 4739-4751.	2.0	20
9	Genistein alters caffeine exposure in healthy female volunteers. European Journal of Clinical Pharmacology, 2011, 67, 347-353.	1.9	17
10	Real-time colorimetric detection of DNA methylation of the PAX1 gene in cervical scrapings for cervical cancer screening with thiol-labeled PCR primers and gold nanoparticles. International Journal of Nanomedicine, 2016, Volume 11, 5335-5347.	6.7	17
11	Searching the Cytochrome P450 Enzymes for the Metabolism of Meranzin Hydrate: A Prospective Antidepressant Originating from Chaihu-Shugan-San. PLoS ONE, 2014, 9, e113819.	2.5	14
12	Quercetin Significantly Inhibits the Metabolism of Caffeine, a Substrate of Cytochrome P450 1A2 Unrelated toCYP1A2*1C  (Ⱂ2964G>A) and1F*(734C>A) Gene Polymorphisms. BioMed Research International, 2014, 2014, 1-6.	1.9	11
13	Quantitative determination of betamethasone sodium phosphate and betamethasone dipropionate in human plasma by UPLC-MS/MS and a bioequivalence study. Analytical Methods, 2016, 8, 3550-3563.	2.7	11
14	NFE2L3 Inhibition Induces Cell Cycle Arrest at the GO/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811. Disease Markers, 2019, 2019, 1-7.	1.3	11
15	Effect of two-linked mutations of the FMO3 gene on itopride metabolism in Chinese healthy volunteers. European Journal of Clinical Pharmacology, 2014, 70, 1333-1338.	1.9	10
16	LC–MS–MS Quantitative Determination of Ursolic Acid in Human Plasma and Its Application to Pharmacokinetic Studies. Chromatographia, 2010, 72, 1107-1113.	1.3	9
17	Validation of a Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Method for Determination of All-Trans Retinoic Acid in Human Plasma and Its Application to a Bioequivalence Study. Molecules, 2014, 19, 1189-1200.	3 . 8	8
18	Kinetics of cytochrome P450 enzymes for metabolism of sodium tanshinone IIA sulfonate in vitro. Chinese Medicine, 2016 , 11 , 11 .	4.0	8

#	Article	IF	Citations
19	Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers. Xenobiotica, 2016, 46, 896-900.	1.1	7
20	Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers. BioMed Research International, 2017, 2017, 1-7.	1.9	7
21	Comparative pharmacokinetic study on three formulations of Astragali Radix by an LC–MS/MS method for determination of formononetin in human plasma. Biomedical Chromatography, 2019, 33, e4563.	1.7	7
22	Development and Validation of a LC–MS/MS Method for the Determination of Ilaprazole Enantiomers and Its Application to a Bioequivalence Study in Healthy Chinese Volunteers. Chromatographia, 2012, 75, 95-101.	1.3	6
23	LC–MS/MS determination of ginsenoside compound K and its metabolite 20Â(S)-protopanaxadiol in human plasma and urine: applications in a clinical study. Bioanalysis, 2019, 11, 365-380.	1.5	6
24	UPLC Analysis of Mycophenolic Acid and Its Phenol and Acyl Glucuronide Metabolites in Human Plasma. Chromatographia, 2010, 72, 747-752.	1.3	4
25	Development and validation of a method for the determination of nicotinic acid in human plasma using liquid chromatography-negative electrospray ionization tandem mass spectrometry and its application to a bioequivalence study. Analytical Methods, 2014, 6, 8258-8267.	2.7	4
26	Simultaneous determination of sulindac and its metabolites sulindac sulfide and sulindac sulfone in human plasma by a sensitive UPLC-PDA method for a pharmacokinetic study. Analytical Methods, 2014, 6, 4679-4685.	2.7	4
27	A Joint Technology Combining the Advantages of Capillary Microsampling with Mass Spectrometry Applied to the Trans-Resveratrol Pharmacokinetic Study in Mice. Journal of Analytical Methods in Chemistry, 2022, 2022, 1-11.	1.6	4
28	LC–MS–MS Quantitative Determination of Brivudine in Human Plasma and Its Application to Pharmacokinetic Studies. Chromatographia, 2011, 73, 1089-1095.	1.3	3
29	Association between polymorphisms in SLC15A1 and PLA2G16 genes and development of obesity in Chinese subjects. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 439-446.	2.4	3
30	Relationship between polymorphisms of the lipid metabolism-related gene PLA2G16 and risk of colorectal cancer in the Chinese population. Functional and Integrative Genomics, 2019, 19, 227-236.	3.5	3
31	Clinical application and importance of one-step human CYP2C19 genotype detection. Journal of International Medical Research, 2018, 46, 4965-4973.	1.0	2
32	Validated LC–MS–MS Method for Quantitative Determination of Batifiban in Human Plasma and Its Application to a Pharmacokinetic Study. Chromatographia, 2009, 70, 415-421.	1.3	1
33	The potent mechanism-based inactivation of CYP2D6 and CYP3A4 with fusidic acid in <i>in vivo</i> bioaccumulation. Xenobiotica, 2018, 48, 999-1005.	1.1	1